Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Dapagliflozin, an SGLT2 Inhibitor, From Oral Hypoglycemic Agent to Antidepressant Drug

NCT07239011 is registered in ClinicalTrials.gov with Tanta University as lead sponsor.

NCT NCT07239011
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07239011 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Dapagliflozin, an SGLT2 Inhibitor, From Oral Hypoglycemic Agent to Antidepressant Drug
Lead sponsor
Tanta University
Phase
Phase 1/2
Overall status
Recruiting
Start date
November 1, 2025
Completion date
December 20, 2026
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

depression